E08A.F Exagen Inc

Healthcare Biotechnology Frankfurt Exchange
4.82 EUR
Close of Nov 12, 2026
2.26 7.85
Market cap
EUR 123M
P/E
-
P/B
12.84x
ROE
-117.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is E08A.F undervalued?

Graham number

The Graham number of Exagen Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Exagen Inc fundamental analysis

No fundamental analysis for Exagen Inc yet.

Exagen Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Exagen Inc

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presen…

Full company profile